Funds and ETFs Orion Oyj

ORNBV

FI0009014377

Name	Weight	AuM	1st Jan change	Investor Rating
XACT NORDIC HIGH DIVIDEND LOW VOLATILITY UCITS ETF - SEK	2.96%	1,331 M€	+7.08%
SELIGSON & CO OMX HELSINKI 25 UCITS ETF - EUR	2.87%	460 M€	+1.47%
HARTFORD MULTIFACTOR DEVELOPED MARKETS (EX-US) ETF - USD	0.35%	1,120 M€	+0.40%
FRANKLIN LIBERTYQ EUROPEAN EQUITY UCITS ETF - EUR	0.32%	3 M€	+9.95%	-
INDEXIQ FACTORS SUSTAINABLE EMU EQUITY UCITS ETF - EUR	0.24%	2 M€	+7.72%
ISHARES EDGE MSCI MULTIFACTOR EAFE INDEX ETF (CAD-HEDGED) - CAD	0.14%	5 M€	+10.09%	-
ISHARES EDGE MSCI MULTIFACTOR EAFE INDEX ETF - CAD	0.14%	14 M€	+5.66%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	0.11%	18 M€	+3.79%	-
AMUNDI MSCI EUROPE EX UK UCITS ETF (C) - EUR	0.07%	6 M€	-.--%	-
UBS (IRL) ETF PLC MSCI EUROPE ESG UNIVERSAL LOW CARBON SELECT UCITS ETF - ACC - EUR	0.03%	6 M€	-.--%
SIMPLIFY DEVELOPED EX-US PLUS DOWNSIDE CONVEXITY ETF - USD	0.02%	10 M€	-3.35%	-
CSIF (IE) MSCI WORLD ESG LEADERS BLUE UCITS ETF - BH - EUR	0.02%	277 M€	-.--%	-
CSIF (IE) MSCI WORLD ESG LEADERS BLUE UCITS ETF - BH - CHF	0.02%	194 M€	+7.48%	-
CSIF (IE) MSCI WORLD ESG LEADERS BLUE UCITS ETF - B - USD	0.02%	441 M€	+10.26%
AMUNDI MSCI WORLD ESG LEADERS SELECT - UCITS ETF DR (C) - USD	0.02%	276 M€	+11.40%	-
AMUNDI INDEX MSCI WORLD UCITS ETF - EUR	0.01%	1,166 M€	+0.26%	-
AMUNDI INDEX MSCI WORLD UCITS ETF DR (D) - EUR	0.01%	607 M€	+0.05%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF ACC - EUR	0.01%	389 M€	+6.83%	-
AMUNDI MSCI WORLD CLIMATE PARIS ALIGNED PAB UCITS ETF DR (C) - USD	0.01%	284 M€	-.--%
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (UNHEDGED) ETF - JPY	0.01%	273 M€	+15.83%
LYXOR MSCI WORLD CLIMATE CHANGE (DR) UCITS ETF - ACC - USD	0.01%	206 M€	-.--%
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF ACC - EUR	0.01%	108 M€	+2.03%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.01%	34 M€	+6.71%	-

Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - generic, OTC and biosimilar drugs (43.4%); - patented prescription products (41.7%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - animal health products (8.7%); - pharmaceutical ingredients and outsourcing services (6.2%). Net sales break down primarily by source of revenue between sales of products (86.9%) and royalties (10.4%). Net sales are distributed geographically as follows: Finland (28%), Scandinavia (12%), Europe (30.8%), North America (14.7%) and other (14.5%).

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Ratings for Orion Oyj

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

35.85 EUR

Average target price

39.2 EUR

Spread / Average Target

+9.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ORION OYJ	-8.71%	5.38B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Market Closed - Nasdaq Helsinki Other stock markets 08:59:53 26/04/2024 pm IST			5-day change	1st Jan Change
35.85 ^EUR	+1.30%		+10.65%	-8.71%

26/04	Orion Corporation Announces Appointments to Nomination Committee	CI
25/04	Transcript : Orion Oyj, Q1 2024 Earnings Call, Apr 25, 2024